October 30, 2019

Despite anatomy being the first topic to challenge the student in medical school for over 150 years, attention to variation of drug targets across tissues in the human body has remained scant even to the present day. GeneCentrix has pioneered the incorporation of trans...

October 30, 2019

It seems like an obvious concept: Let's say you are developing a drug that works by inhibiting, say, phosphodiesterase-4 (PDE-4) to treat depression (fictional). You have collected immense molecular, cellular, animal and clinical data supporting and validating PDE-4 as...

October 30, 2019

Artificial intelligence (AI) conjures up images of Terminators and human enslavement to machines, but, in fact, AI is already a huge and welcome part of our iPhone driven lives, guiding us in everything from getting to the nearest burrito to keeping our mailbox free of...

October 1, 2019

After the euphoria of the discovery of the viral cause of AIDS (1984) came the growing (e.g. Dallas Buyer’s Club) desperation as that discovery failed to translate into an effective treatment for many years.  Fortunately, the low hanging fruit was plucked, as several r...

October 1, 2019

You gotta walk before you can run.  Actually, you usually have to crawl before you walk.  For small molecule drug discovery in the early days, we were talking more about not moving at all from serendipitous discoveries, with maybe a little floundering around in the hop...

October 1, 2019

The spice turmeric has long been touted as having magical medical properties.  From cancer to rheumatism, the ancients swore by it, and a large number of individuals today worldwide still believe in its medicinal properties.  

But modern pharmaceutical science...

August 29, 2019

One of the FDA’s crowning achievements historically was its rejection of the not-ready-for-prime-time drug, thalidomide, in the 1950s, while their counterparts in Europe approved it to devastating results.  That and other success stories of the US FDA’s risk-averse sta...

August 29, 2019

Bristol-Myers-Squibb (BMS) purchased Celgene some months ago, much to the consternation of BMS’s biggest shareholder, who felt it was too big an acquisition, and also many Celgene shareholders, who felt the companies prospects were brighter than what was implied in the...

August 29, 2019

The saying “fool me once, shame on you; fool me twice, shame on me!” could be proposed as applying to drug discovery targeting the oncogene Ras to treat cancer, but it would be more like “fool me all 100 times and all in a row, shame on everybody.” Ever since the Ras g...

July 26, 2019

Mankind would be nowhere without respect for the fundamentals.  And search might be the most fundamental process of all.  Faster ways to find information might sound boring, but we literally use those advances every second.  Remember the phone book? (Shudder) We rememb...

Please reload

THE GENE

EXPRESS

Recent News

Swede success

October 30, 2019

A tissue a tasket

October 30, 2019

Metal ahead

October 30, 2019

1/4
Please reload

Tags